Market Newsdesk

NORTH TONAWANDA, N.Y., March 26, 2021 /PRNewswire/ — Taylor Devices, Inc. (NASDAQ SmallCap: “TAYD”) announced today that it had 3^rd quarter Net earnings of $182,318, down from last year’s 3^rd quarter Net earnings of $782,752.  Net earnings for the 1^st nine months were $1,003,619, also down from last year’s Net earnings for the 1^st nine months of $2,054,335.

Sales for the 3^rd quarter were $4,772,371, lower than last year’s 3rd quarter sales of $7,234,195.  Sales for the 1^st nine months were $15,249,425, lower than last year’s 1^st nine months sales of $20,645,259.

“Sales this quarter and YTD are significantly lower than this period last year with earnings likewise lower but not as low as they would have otherwise been due to the federal aid we received as an incentive to keep employees hired during the pandemic,” stated Tim Sopko, CEO.  He further commented, “The accelerated progress made on our Continuous Improvement initiatives during this time of lower business volume positions us well to execute more efficiently at higher business volumes as our markets rebound from the negative impacts of the virus.”  He concluded, “While it remains to be seen how the impacts of the pandemic will play out on our path forward, booking activity has been on the rise this past quarter with YTD bookings almost $3,000,000 better than this time last year, which is encouraging.”  

The company’s firm order backlog is $18,800,000 at the end of February as compared to $14,600,000 at this time last year.   

Taylor Devices, Inc. is a 66-year old company engaged in the design, development, manufacture and marketing of shock absorption, rate control and energy storage devices for use in various types of vehicles, machinery, equipment and structures.  The company continues to target growth in the domestic Aerospace and Defense market as well as global Structural Construction and Industrial markets. 

 

Taylor’s website can be visited at:  www.taylordevices.com ; with company newsletters and other pertinent information at www.taylordevices.com/investors.

Taylor Devices, Inc.

View original content:http://www.prnewswire.com/news-releases/taylor-devices-announces-third-quarter-and-nine-month-results-301256744.html

SOURCE Taylor Devices, Inc.

TORONTO, March 26, 2021 /PRNewswire/ – Pivotree Inc. (TSXV: PVT) (“Pivotree” or the “Company“), a leading global commerce and master data management (MDM) services provider, today announced its strategic partnership with Noibu Technologies, a leader in eCommerce error monitoring and lost revenue prevention.

Noibu offers a software-as-a-service (SaaS) product that allows retailers to detect, prioritize, and resolve revenue-impacting errors on their eCommerce sites. Through its work with some of the world’s leading brands, Pivotree has the development capabilities required to gather Noibu’s findings, monitor issues, and apply strategic resolutions — delivering an end-to-end service for its clients.

“Even for eCommerce leaders that perform extensive testing, checkout bugs occur because of browser plugins or other third applications. We’re pleased to announce that, through this partnership, we can help solve this challenge for our clients,” said Greg Wong, Chief Revenue Officer at Pivotree. “Noibu’s platform is an ace up the sleeve of our world-class commerce specialists who will be able to precisely locate the most revenue-impacting bugs closer to the moment they appear than ever before, preventing them from causing potentially millions of dollars in lost revenue.”

Without an advanced monitoring service, eCommerce brands either have to identify negative trends in errant customer behavior through analytics or rely on end-consumers to notify the business. Noibu’s platform allows Pivotree to see bugs as they happen, understand the steps to take to replicate them, and then prioritize them for debugging. With the recent evolution in digital commerce, these factors have become more critical to the customer experience and overall revenue for brands.

“The past year has changed how customers interact with brands entirely, with some companies seeing most or all of their business driven from online sales. These factors make revenue-impacting website errors more threatening than ever for businesses,” said Kailin Noivo, Co-founder and VP of Sales at Noibu. “Our partnership with Pivotree will help us reach more clients on enterprise eCommerce platforms who can rely on Pivotree’s world-class eCommerce experts to resolve these issues quickly and effectively.”

Whether researching a product or making a purchase, a retailer’s eCommerce site is a critical point in the customer journey. Given the rise of eCommerce during the COVID-19 pandemic, brands must put greater emphasis on delivering seamless eCommerce experiences as part of a larger Frictionless Commerce strategy. Pivotree helps brands adopt Frictionless Commerce holistically, addressing friction as an end-to-end issue, from raw materials to final delivery and customer service.

“Noibu helps by identifying friction at the moment of purchase, where bugs can often prevent companies from maximizing revenue, and our audits on large eCommerce sites have been identifying 7-digit revenue-impacting bugs,” adds Wong. “Our clients out-perform their respective industry averages, so the addition of Noibu gives them an additional competitive edge to deliver a more Frictionless Commerce experience.”

Pivotree released the 2021 Delivering Frictionless Commerce Report with Environics earlier this year to help guide brands through creating Frictionless Commerce experiences.

To learn more about how companies will benefit from the Pivotree and Noibu offering, or to inquire about a free 14-day site audit, click here.

About Noibu Technologies
Serving enterprise customers globally, Noibu is the industry leader in eCommerce error monitoring and lost revenue prevention. Noibu’s software platform monitors your eCommerce site and flags and prioritizes errors that prevent real customers from checking out, while collecting all the information required to quickly resolve them. For more information, visit www.noibu.com.

About Pivotree
Pivotree is a leading global commerce and MDM services provider. It is an end-to-end vendor supporting clients from strategy, platform selection, deployment, and hosting through to ongoing support. It operates as a single expert resource to help companies adapt relentlessly in an ever-changing digital commerce landscape. Leading and innovative clients rely on Pivotree’s deep expertise to choose enterprise-proven solutions and design, build, and connect critical systems to run smoothly at defining moments in a commerce business. Pivotree serves as a trusted partner to over 170 market-leading brands and forward-thinking B2C and B2B companies, including many companies in the Fortune 1000. With offices and customers in the Americas, EMEA, and APAC, Pivotree is widely recognized as a high-growth company and industry leader around the globe. For more information, visit http://www.pivotree.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pivotree-and-noibu-announce-strategic-partnership-for-comprehensive-ecommerce-error-monitoring-and-resolution-301256735.html

SOURCE Pivotree Inc.

Acquisition Targets Incubating Travel Wear Market, Provides Centralized Operational Costs, Augments Ecommerce and Capital Market Expertise

VANCOUVER, BC, March 26, 2021 /PRNewswire/ – RYU Apparel Inc. (TSXV: RYU) (OTCQB: RYPPF) (FWB: RYAA)  (“RYU” or the “Company“), creator of urban athletic apparel, is pleased to announce that it has entered into a share exchange agreement dated March 24, 2021 (the “Agreement“) with Kosan Travel Company Ltd., a private arm’s length British Columbia corporation (“Kosan“), and the shareholders of Kosan (collectively, the “Vendors“), pursuant to which RYU has agreed to acquire all of the issued and outstanding shares of Kosan from the Vendors (the “Transaction“).

Cesare Fazari, CEO of RYU stated, “We are excited at the prospect of having Kosan join the RYU family. We expect a big resurgence of travel in 2022 and intend to capitalize on the increased demand as consumers emerge from the pandemic. Whether it is heading out across the country or back out across the world, we believe Kosan’s functional travel apparel will be a hit with RYU customers and new customers alike. We also believe Kosan’s alignment with our message of RESPECT and its predominantly millennial female audience will augment our brand in a key market that we are focusing on.”

About Kosan Travel Company Ltd.

Kosan was co-founded by Joel Primus, who is intended to remain as the CEO of Kosan in addition to assisting RYU’s leadership team and corporate objectives. Joel was the founder and creative visionary behind numerous products at Naked Underwear (NASDAQ:NAKD), establishing retail distribution at Holt Renfrew, Nordstrom, Hudson’s Bay, and Bloomingdales, as well as brokering celebrity partnerships and up-listing the company to the Nasdaq. He was an inaugural British Columbia Business top 30 under 30 Entrepreneur in 2014 and has appeared on CBC’s hit show Dragon’s Den.

Kosan is a web-based travel apparel provider with a core focus on stylish performance dresses, rain jackets and bags that make adventures safer, easier and more comfortable. The brand achieved success on the well-known crowdfunding platform Kickstarter. The brand achieved nearly $1M in sales over a 35-day period, making it one of the platforms most successful apparel campaigns in history.

Kosan has built a loyal community of travelers across the world by creating beautiful but functional travel wear made from high quality materials. Kosan sells its popular travel dresses in over 70 countries. The brand has been featured in well-known publications such as Forbes, Travel + Leisure, SELF and Fodor’s. Kosan’s premium clothing can be seen on travel influencers and digital nomads from around the globe on travel blogs, Instagram models, and Tik Tok influencers.

Kosan’s unaudited net sales for the year ended May 31, 2020 were CAD$944,147 with an achieved gross margin¹ of 39%.

“Kosan was seeing impressive growth before the pandemic hit. With the travel market predicted to return bigger than ever, we hope that by joining up with RYU, we will get that traction back faster than we could on our own,” said Primus. “We are confident that RYU’s product development platform, distribution network, and marketing channels will enable us to scale growth, reduce cost structures, and exceed our goals for 2022.”

Terms of the Transaction

The purchase price for the Transaction will be $4,000,000 worth of common shares (each, a “Share“) in the capital of RYU, with the number of Shares issuable based on the volume-weighted average closing price of the Shares on the TSX Venture Exchange (“TSXV“) over the thirty (30) trading-days prior to the closing of the Transaction (“Closing“), or such other price as determined by the TSXV in accordance with its policies.

Closing is subject to Kosan raising at least $175,000 in equity financing and a number of other conditions common to similar share exchange transactions, including the conditional approval of the TSXV.  Closing is also subject to Kosan having no more than $90,000 in aggregate indebtedness on the closing date.

The Company anticipates that the Transaction will constitute an Expedited Transaction in accordance with the policies of the TSXV.

For regular updates on RYU Apparel visit: http://ryu.com

Note:

About RYU

RYU Apparel (TSXV: RYU, OTCQB: RYPPF), or Respect Your Universe, is an award winning urban athletic apparel and accessories brand engineered for the fitness, performance and lifestyle of the athletic man and woman. Designed without compromise for fit, comfort, and durability, RYU exists to facilitate optimal human performance. For more information, please visit the RYU website at: http://ryu.com  

About Kosan

Kosan creates beautiful, functional travel wear with the finest materials and best factories from around the world. Their customers live active lives, travel the world and explore their own backyards! Kosan’s community spans 74 countries and transcends geography, language, culture and actively champions respect for human rights, equality, and environmental awareness. Kosan’s core products are performance dresses, rain jackets and bags that make your adventures safer, easier and more comfortable. They also donate 1% of its profits to Amnesty International, an organization supporting and advocating for human rights causes around the world.

RYU APPAREL INC.

“Cesare Fazari“
 

Cesare Fazari, CEO
Tel: (844) 535–2880

Notice Regarding Forward
–
Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include the statements respecting the Transaction and the closing thereof, the Company’s expectation that there will be a resurgence of travel in 2021, the expected benefits of the Transaction for both RYU and Kosan and that Joel Primus is anticipated to remain as CEO of Kosan post-closing. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: that the Company’s assumptions in making forward-looking statements may prove to be incorrect; adverse market conditions; the inability of RYU to complete the Transaction on the terms announced or at all; risks relating to the satisfaction of the conditions to closing the Transaction; that future results may vary from historical results; and that market conditions or competition may affect the outcome of the Transaction and the business plan and operations of the Company in the future. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange Inc.) accepts responsibility for the adequacy or accuracy of this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ryu-apparel-announces-proposed-acquisition-of-vancouver-based-kosan-travel-apparel-301256640.html

SOURCE RYU Apparel Inc.

IRVINE, Calif., March 26, 2021 /PRNewswire/ — For the second consecutive year, the Kia Telluride was named the “Best 3-Row SUV for Families” by U.S. News & World Report. Winners were selected based on excellent professional automotive reviews, safety and reliability ratings, and the availability of family friendly features that keep occupants connected and entertained. Vehicles with the highest composite score in their class were named the Best Car for Families in their respective categories.

“For Telluride to take top honors in the Best 3-Row SUV for Families category for the second consecutive year speaks to the safety, technology and comfort our three-row SUV offers,” said Russell Wager, vice president, marketing, Kia Motors America. “From the beginning, Telluride has exceeded even our own high expectations and we are honored that both consumers and media recognize Kia’s commitment to delivering world-class vehicles.”

Aside from high safety and reliability ratings, the 2021 Best Cars for Families were chosen on their family-friendly technological merits. Features such as in-car wireless internet, teen driver controls, automatic braking, surround-view parking camera systems and hands-free cargo doors helped Telluride rise above its competition.

“The Kia Telluride is packed with available features that make life easier and a little bit safer for families,” said Jamie Page Deaton, executive editor of autos, U.S. News & World Report. “Standouts include front automatic braking, lane keep assist, tools for parents to set limits with teen drivers, and comfort and infotainment features like tri-zone climate control, Apple CarPlay/Android auto, and rear-seat sunshades.”

About Kia Motors America

Headquartered in Irvine, California, Kia Motors America continues to top quality surveys and is recognized as one of the 100 Best Global Brands. Kia serves as the “Official Automotive Partner” of the NBA and offers a complete range of vehicles sold through a network of more than 750 dealers in the U.S., including cars and SUVs proudly assembled in West Point, Georgia.*

For media information, including photography, visit www.kiamedia.com. To receive custom email notifications for press releases the moment they are published, subscribe at www.kiamedia.com/us/en/newsalert.

*The Telluride, Sorento and K5 are assembled in the United States from U.S. and globally sourced parts.

About U.S. News & World Report

Since 2007, U.S. News Best Cars, the automotive channel of U.S. News & World Report, has published rankings of the majority of new vehicles sold in America. Each year, U.S. News also publishes the Best Cars awards, including Best Vehicle Brands, Best Cars for the Money and Best Cars for Families. U.S. News Best Cars supports car shoppers throughout the entire car-buying journey, offering advice for researching cars, finding cars for sale near you and getting the best rate on car insurance. U.S. News Best Cars had more than 73 million visitors over the past year, with the majority actively shopping for a car. More than 70% of active shoppers reported that U.S. News influenced their car-purchasing decision, saying that they trust the advice to be unbiased and that they would recommend the site to others.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/kia-telluride-named-best-3-row-suv-for-families-by-us-news–world-report-301256625.html

SOURCE Kia Motors America

AIRPORT CITY, Israel, March 26, 2021 /PRNewswire/ — MySize, Inc (the “Company” or “My Size”) (NASDAQ: MYSZ) (TASE: MYSZ), the developer and creator of e-commerce measurement solutions, today announced the full integration of their e-commerce shoe sizing solution directly to retailers’ websites. The integrated sizing solution, which joins a growing list of additional capabilities to the MySizeID platform, which includes garment and shoe recommendations. This latest addition is intended to enhance customers’ online shopping experience and reduce the hassle of returns for retailers.

Through MySize’s hyper-accurate shoe sizing solution seamlessly built-in as a feature on retailers’ sites, customers will benefit from an ultra streamlined shopping experience, allowing them to virtually obtain fits for a brand’s shoes without needing to download an app. Retailers can provide customers with an incredibly accurate and user friendly sizing solution that will boost their bottom lines and significantly cut down on returns.

As e-commerce footwear sales are slated to reach $21.4 billion in 2021, alongside market size growth recorded at 9.0% per year on average between 2016 and 2021, it’s clear that online shoe sales are a major source of revenue for retailers. But as up to 40% of online footwear purchases are returned, sellers are struggling with costs that top billions annually. The industry is well-positioned to embrace technology that gives customers peace of mind regarding their fits and reduces the risk of returns for retailers.

The MySize footwear sizing solution is easy to implement and is “plug and play” with leading e-commerce platforms Shopify, WooCommerce, Lightspeed, Magento, and more. By pairing a footwear retail’s product table, GTIN, description, and other relevant details with MySize’s AI-driven and machine learning algorithms online shoppers will be presented with a highly accurate size recommendation, which is expected to increase confidence and reduce returns.

MySize has repeatedly demonstrated the positive impact of its highly accurate online sizing solution in the online apparel industry, reducing returns by as much as 50%, and increasing average order value by as much as 30%. Utilizing this same technology, MySize’s footwear solution enables customers to receive a highly accurate shoe size recommendation that is saved, using the current wizard.

“When customers can order the right size without needing to jump through hoops or rely on guesswork, both the retailer and the consumer win,” said Ronen Luzon, CEO, and Founder of MySize. “By bringing our highly accurate sizing tech directly to retailers’ sites, we’re empowering larger numbers of customers to obtain the right fit for them, and increasing accessibility to those who may not have wanted to take the extra step of downloading the app. In 2021, consumers expect an online shopping experience that covers them from A to Z, and with our built-in sizing feature, retailers can provide their customers with the very best virtual fits.”

About MySize Inc:

My Size, Inc. (TASE: MYSZ, NASDAQ: MYSZ) has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications, including the apparel, e-commerce, DIY, shipping, and parcel delivery industries. This proprietary measurement technology is driven by several algorithms that are able to calculate and record measurements in a variety of novel ways. To learn more about My Size, please visit our website: www.mysizeid.com. We routinely post information that may be important to investors in the Investor Relations section of our website. Follow us on Facebook, LinkedIn, Instagram, and Twitter.

Please click here for a demonstration of how MySizeID provides a full sizing solution for the retail industry.

Register here for a free plan of MySizeID solution for your online store.

 Please click here to download MySizeID for iOS.

Please click hereto download MySizeID for Android.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

U.S. Press Contact:

Strauss Communications  
[email protected]  
www.strausscomms.com

IR Contact:

Or Kles, CFO
[email protected]

 

 

 

View original content:http://www.prnewswire.com/news-releases/mysize-debuts-seamless-integration-of-ecommerce-footwear-sizing-solution-to-retailers-websites-bringing-highly-accurate-sizing-directly-to-online-shoppers-301256649.html

SOURCE My Size Inc.

TOKYO, March 26, 2021 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) approved Myrbetriq^® (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq^® Granules (mirabegron for extended-release oral suspension) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older. The FDA also granted pediatric exclusivity for Myrbetriq, resulting in an additional six month period of market exclusivity.

Myrbetriq and Myrbetriq Granules are first-in-class to now be FDA-approved for children with NDO. Treatment options for NDO have been limited or invasive, including scheduled toileting, catheterization, or surgery.^[1]  If left untreated, NDO can lead to the deterioration of urinary tract function at an early age.^[2] 

“With this latest approval, Astellas is bringing forward a new treatment option for children impacted by NDO, an especially vulnerable patient population with high unmet need,” said Salim Mujais, M.D., senior vice president and head, Medical Specialties, Astellas. “This approval marks a significant milestone for patients living with this rare but serious bladder condition that can cause unwanted accidents.”^[3] 

NDO is a type of bladder dysfunction caused by nerve damage and is marked by uncontrolled bladder contractions that can lead to symptoms of urinary frequency, urgency and incontinence.^[1] Eighty-five percent of children with NDO have spina bifida, a congenital spinal cord defect.^[3]

Myrbetriq tablets (mirabegron extended-release tablets) are currently available in the U.S. Myrbetriq Granules (mirabegron for extended-release oral suspension) were developed for ease of administration in younger children with NDO, or children with NDO who may have difficulty swallowing tablets, and will be available in the U.S. by the end of 2021.

“Astellas is a long-time leader in the field of urologic health and is committed to advancing the treatment of bladder conditions that adversely impact the lives of patients,” continued Mujais. “Since its initial approval nine years ago, Myrbetriq has been used to treat nearly 18 million adult patients worldwide with urological conditions.”^[4]

The approval for the NDO indication was based on findings from a Phase 3 pivotal study that evaluated the efficacy, safety, tolerability and pharmacokinetics of mirabegron in children and adolescents (aged 3 to <18 years) with NDO and using clean intermittent catheterization (ClinicalTrials.gov Identifier: NCT02751931).

Astellas has already reflected the impact from this FDA approval in its financial forecast for the current fiscal year, ending March 31, 2021.

USE OF MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ GRANULES (mirabegron for extended-release oral suspension)

• Myrbetriq (mirabegron extended-release tablets) for oral use is a prescription medicine used to treat children 3 years of age and older weighing at least 77 pounds (35 kg), with a condition called neurogenic detrusor overactivity (NDO).
• Myrbetriq Granules (mirabegron for extended-release oral suspension) is a prescription medicine used to treat children 3 years of age and older with a condition called neurogenic detrusor overactivity (NDO).

It is not known if Myrbetriq tablets and Myrbetriq Granules to treat NDO are safe and effective in children under 3 years of age.

IMPORTANT SAFETY INFORMATION

Do not take Myrbetriq tablets or Myrbetriq Granules if you are allergic to mirabegron or any ingredients in Myrbetriq tablets or Myrbetriq Granules.

Myrbetriq tablets and Myrbetriq Granules may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. You and your doctor should check your blood pressure while you are taking Myrbetriq tablets or Myrbetriq Granules. Call your doctor if you have increased blood pressure.

Myrbetriq tablets and Myrbetriq Granules may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream.

Myrbetriq tablets and Myrbetriq Granules may cause an allergic reaction with swelling of the face, lips, throat or tongue with or without difficulty breathing. Stop taking Myrbetriq tablets or Myrbetriq Granules and go to the nearest hospital emergency room right away.

Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines especially thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®) or solifenacin succinate (VESIcare®). Myrbetriq tablets and Myrbetriq Granules may affect the way other medicines work, and other medicines may affect how Myrbetriq tablets and Myrbetriq Granules works.

Before taking Myrbetriq tablets and Myrbetriq Granules, tell your doctor about all of your medical conditions, including if you have liver or kidney problems.

The most common side effects of Myrbetriq tablets and Myrbetriq Granules in children with neurogenic detrusor overactivity include urinary tract infection, pain or swelling of the nose or throat (nasopharyngitis), constipation, and headache.

For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1
–
800
–
FDA
–
1088.

About Astellas
Astellas Pharma Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+^® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

[1] Hristov KL, Afeli SAY, Parajuli SP, Cheng Q, Rovner ES, et al. Neurogenic detrusor overactivity Is associated with decreased expression and function of the large conductance voltage- and Ca2+ -activated K+ channels. PLoS ONE 2013;8(7):1-8.

[2] McKibben MJ, Seed P, Ross SS, Borawski KM. Urinary Tract Infection and Neurogenic Bladder. Urol Clin North Am. 2015;42(4):527-536. 

[3] Bauer SB, Austin PF, Rawashdeh YF, de Jong TP, Franco I, Siggard C, et al. International Children’s Continence Society’s recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012;31:610-4.

[4] Astellas. Myrbetriq. Data on File. 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/astellas-garners-new-indication–new-product-formulation-approvals-from-us-fda-for-children-with-neurogenic-detrusor-overactivity-ndo-301256674.html

SOURCE Astellas Pharma Inc.